RLM.L

Realm Therapeutics Plc
Realm Therapeutics - Cancellation of AIM Listing
26th March 2019, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9555T
Realm Therapeutics PLC
26 March 2019
 

Realm Therapeutics plc

("Realm", "Realm Therapeutics" or the "Company")

 

Cancellation of AIM Listing

 

 

 

MALVERN, PA, March 26, 2019 - Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, announced on March 15, 2019 that the listing of the Company's Ordinary Shares on AIM will cease and cancellation will be effective from 7:00 a.m. (GMT) on March 27, 2019.

 

Accordingly, today will be the last day of trading of Realm's Ordinary Shares on AIM. Information on how to convert Ordinary Shares to American Depositary Shares ("ADSs") is available on the Company's website at www.realmtx.com.

 

With effect from March 27, 2019, on the basis that the Company's place of central management and control is outside of the UK, Channel Islands and the Isle of Man, whilst the sale process continues, the Takeover Code will no longer apply to the Company and the process will no longer be a "formal process" under the Takeover Code.

 

Capitalized terms used but not defined in this announcement shall have the meanings given to them in the circular sent to Realm shareholders on 15 February 2019, which remains available on the Company's website at www.realmtx.com.

 

RNS-RLM

 

About Realm Therapeutics

 

For more information on Realm Therapeutics, please visit www.realmtx.com.

 

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements. These forward-looking statements reflect the Company's judgment at the date of this announcement and are not intended to give any assurance as to future results. Except as required by the FCA, the London Stock Exchange, the Panel on Takeovers and Mergers, the AIM Rules for Companies or applicable law, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in the Company's expectations about them or any changes in events, conditions or circumstances on which any such statement is based.

 

Contacts:

Realm Therapeutics plc


Alex Martin, Chief Executive Officer


Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside U.S.:  +44 (0) 20 3727 1000

U.S.:  +1 212 600 1902

 

Argot Partners

Stephanie Marks / Claudia Styslinger

+1 212 600 1902

 

FTI Consulting


Simon Conway

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCLELLLKXFZBBZ ]]>
TwitterFacebookLinkedIn